Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

Inclusion Criteria: * Capable of and willing to provide informed consent * Evidence of HIV infection (either HIV-seropositive, CD4+ T-cell count of ≤350/mm3 or other clinically accepted indicator) * An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size, or a recent history of unintentional weight loss of 10% from the subjects baseline * Weight losses was clinically associated with AIDS-related wasting and not related to any other disease process * Women of childbearing potential had to agree to use effective contraception for the duration of the study and for two weeks after the last dose * Clinical laboratory values had to be within normal limits or out-of-range limits must be designated as not clinically significant (some exceptions per protocol) * Able to read and write in the study related documents translated into the primary local language * Capable of and willing to return to the clinic regularly for study visits * Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry * Capable of completing a 3-day food intake diary with instruction * Willing to abstain from any illegal or recreational drug substances for the duration of the trial * Willing to abstain from taking any other medications or substances known to affect appetite or weight gain (eg, steroids \[other than those inhaled for treatment of asthmatic conditions\], nutritional supp…